Biofil Chemicals & Pharmaceuticals Hits New 52-Week Low at Rs. 40.21

Biofil Chemicals & Pharmaceuticals has reached a new 52-week low, hitting Rs. 40.21 today, October 7, 2025. This marks a significant decline for the microcap company, which has seen a 40.10% decrease in its stock price over the past year, contrasting sharply with the Sensex's modest gain of 1.33% during the same period.
Despite today's drop, Biofil has outperformed its sector by 1.92% and has recorded a consecutive gain over the last two days, rising 2.39%. However, the stock remains below its 20-day, 50-day, 100-day, and 200-day moving averages, indicating a challenging market position.

The company's long-term fundamentals show a concerning trend, with a -25.47% compound annual growth rate in operating profits over the last five years and a weak EBIT to interest ratio of 0.81. Additionally, Biofil's return on equity stands at a modest 4.38%, reflecting low profitability relative to shareholders' funds.

As the market continues to evolve, Biofil Chemicals & Pharmaceuticals faces significant hurdles in improving its financial standing and overall performance.